GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) was down 6.2% on Thursday . The stock traded as low as $98.02 and last traded at $98.75. Approximately 217,041 shares were traded during trading, a decline of 64% from the average daily volume of 596,225 shares. The stock had previously closed at $105.31.
Analysts Set New Price Targets
A number of research firms have recently commented on WGS. TD Cowen increased their price objective on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. The Goldman Sachs Group increased their price objective on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $72.33.
Get Our Latest Stock Analysis on GeneDx
GeneDx Stock Up 0.8 %
The business has a 50 day moving average of $83.24 and a 200-day moving average of $67.70. The stock has a market cap of $2.75 billion, a PE ratio of -50.00 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. Equities research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, CEO Katherine Stueland sold 51,420 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at $162,505.60. This trade represents a 96.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin Feeley sold 3,728 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $76.75, for a total value of $286,124.00. Following the completion of the sale, the chief financial officer now directly owns 28,200 shares of the company's stock, valued at $2,164,350. This represents a 11.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,321 shares of company stock valued at $11,315,903. 27.30% of the stock is owned by company insiders.
Institutional Trading of GeneDx
Hedge funds have recently modified their holdings of the business. Polar Asset Management Partners Inc. purchased a new position in GeneDx in the 4th quarter valued at approximately $1,007,000. Palisades Investment Partners LLC purchased a new position in GeneDx in the 4th quarter valued at approximately $6,425,000. Castleark Management LLC purchased a new position in GeneDx in the 4th quarter valued at approximately $4,743,000. PharVision Advisers LLC purchased a new position in GeneDx in the 4th quarter valued at approximately $301,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in GeneDx by 120.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 16,849 shares of the company's stock valued at $1,295,000 after purchasing an additional 9,202 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.
GeneDx Company Profile
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
See Also
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
